DYRK1A Protein, A Promising Therapeutic Target to Improve Cognitive Deficits in Down Syndrome
Down syndrome (DS) caused by a trisomy of chromosome 21 (HSA21), is the most common genetic developmental disorder, with an incidence of 1 in 800 live births. Its phenotypic characteristics include intellectual impairment, early onset of Alzheimer’s disease, congenital heart disease, hypot...
Main Authors: | Anis Feki, Youssef Hibaoui |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-10-01
|
Series: | Brain Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/2076-3425/8/10/187 |
Similar Items
-
Concise Review: Methods and Cell Types Used to Generate Down Syndrome Induced Pluripotent Stem Cells
by: Youssef Hibaoui, et al.
Published: (2015-04-01) -
Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A
by: Thu Lan Nguyen, et al.
Published: (2018-09-01) -
Skeletal Deficits in Male and Female Mouse Models of Down Syndrome
by: Thomas, Jared
Published: (2020) -
Synthèse totale et évaluation biologique d’un inhibiteur d’origine naturelle de la kinase DYRK1A
by: Lucas, Romain
Published: (2014) -
DYRK1A-mediated Cyclin D1 Degradation in Neural Stem Cells Contributes to the Neurogenic Cortical Defects in Down Syndrome
by: Sònia Najas, et al.
Published: (2015-02-01)